| Ytd | 3.53% | |
| 1y | 37.61% |
| Open | 782.44 | Prev Close | 794.19 | Low | 779.08 | High | 802.78 | Mkt Cap | 82.27B |
| Vol | 894.13K | Avg Vol | 873.50K | EPS | 40.42 | P/E | 19.77 | Forward P/E | 13.18 |
| Beta | 0.19 | Short Ratio | 3.00 | Inst. Own | 93.51% | Dividend | 3.76 | Div Yield | 0.47 |
| Ex Div Date | 08-18 | Earning | 10-28 | 50-d Avg | 716.62 | 200-d Avg | 728.69 | 1yr Est | 840.43 |
REGN News
This timeline-focused notice highlights allegations that Regeneron's Phase III Fianlimab-Libtayo dis
LOS ANGELES, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shar
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in
New class action for Regeneron (REGN) urges investors to seek recovery for alleged securities fraud
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagen
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem
SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Reg
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
LOS ANGELES, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shar
Control-person liability allegations focus on Regeneron executives' alleged authority over public cl
San Francisco, California--(Newsfile Corp. - August 27, 2026) - Hagens Berman Sobol Shapiro LLP aler
SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Reg
San Diego, California--(Newsfile Corp. - August 26, 2026) - Robbins LLP reminds investors that a sec
New class action for Regeneron (REGN) urges investors to seek recovery for alleged securities fraud
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
This promise-vs-reality notice focuses on allegations that Regeneron promoted Phase I Fianlimab-Libt
NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has
SAN FRANCISCO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- SueWallSt alerts investors in Regeneron Pharmaceuticals,
LOS ANGELES, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Regeneron Pharmaceutical
Regeneron Pharmaceuticals ends August on a high note. The decline in U.S. sales of Eylea following t
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17%
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
SAN FRANCISCO, Aug. 24, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Reg
LOS ANGELES, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shar
Institutional investors with REGN positions may need to assess alleged clinical-trial disclosure fai
Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven
Bill Ackman gifted $400 million of his Pershing Square stake to a brain research foundation after hi
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration
Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.69%
China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s
https://www.newswire.ca/news-releases/libtayo-r-cemiplimab-for-injection-receives-health-canada-appr
Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and r
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Secto
Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a
Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a O
Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-W
Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a
Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $14.29 per share which beat t
Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety da
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and r
For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "
Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overwei